&nbsp;

Jun 2024

Drug

bendamustine

Other Name(s): Treanda®

Quick Link(s):

Nov 2024

Drug

brentuximab vedotin

Other Name(s): Adcetris®

Quick Link(s):

Sep 2024

Drug

blinatumomab

Other Name(s): Blincyto®

Quick Link(s):

Nov 2024

Regimen

TEMS

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

New Drug Funding Program

Temsirolimus - Metastatic Renal Cell Carcinoma

Drugs Used:

temsirolimus

Quick Link(s):

Regimen Monograph

Jun 2024

Regimen

BMP

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Previously Untreated - Multiple Myeloma

ODB - General Benefit

melphalan - oral tablets

ODB - General Benefit

prednisone

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2019

Regimen

BORT

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Relapsed or Refractory Multiple Myeloma

ODB - General Benefit

dexamethasone

Drugs Used:

bortezomib,

dexamethasone

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

TRAS

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) in combination with Chemotherapy - Metastatic Breast Cancer

New Drug Funding Program

Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer

Drugs Used:

trastuzumab

Quick Link(s):

Regimen Monograph

May 2024

Regimen

TRAS

Cancer Type:

Breast

Intent: Adjuvant

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer

Drugs Used:

trastuzumab

Quick Link(s):

Regimen Monograph

Feb 2022

Regimen

BEND

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

New Drug Funding Program

Bendamustine - First Line - Chronic Lymphocytic Leukemia

Drugs Used:

bendamustine

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

BEND+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Bendamustine - First Line - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

New Drug Funding Program

Bendamustine - Relapsed_Refractory - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

Drugs Used:

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Nov 2024

Regimen

BREN

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Intermediate Grade,

Lymphoma - T-cell

Intent: Palliative

Funding:

New Drug Funding Program

Brentuximab Vedotin - Systemic Anaplastic Large Cell Lymphoma

Drugs Used:

brentuximab vedotin